Loading, Please Wait...
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2018.
“This is an exciting time for the Company. We are diligently working toward database lock for VTL-308 and expect to report topline results in the second half of September,” said Russell J. Cox, the Company’s Chief Executive Officer. “Additionally, we continue with preparations for the potential submission of a biologics license application and commercial launch of ELAD.”
Key Recent Developments
Second Quarter 2018 Financial Results
Cash and cash equivalents at June 30, 2018, totaled $31.1 million compared to $56.9 million at December 31, 2017. The Company expects its use of funds will change based on the results of the VTL-308 clinical trial.
Results of Operations
Three Months Ended June 30, 2018
The Company reported a net loss of $12.7 million for the three months ended June 30, 2018, which compared with a net loss of $12.4 million for the same prior year period. This resulted in a net loss of $0.30 per share for the three months ended June 30, 2018, as compared to a net loss of $0.29 per share for the corresponding period in 2017, on both a basic and diluted basis.
Research and development expenses decreased to $8.7 million for the three months ended June 30, 2018 as compared to $9.8 million for the three months ended June 30, 2017. General and administrative expenses were $4.3 million for the three months ended June 30, 2018, as compared to $2.7 million for the three months ended June 30, 2017.
Conference Call Details
Vital Therapies will host a conference call to discuss these results and provide a corporate update today at 4:30 PM ET, which will be open to the public. The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 9287366. Participants can access the live webcast via a link on the Vital Therapies website in the Investor Relations section under “Events” at: http://ir.vitaltherapies.com/.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 9287366.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying the conduct of our clinical trials and the timing of the release of the results, and our cash use . Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
Risks and uncertainties include, but are not limited to, difficulty maintaining regulatory approvals in the United States or Europe, in particular for a combination product and open-label clinical trials; our limited experience in conducting pivotal clinical trials and significant issues regarding our clinical trials such as clinical sites’ adherence to protocols; assumptions regarding the number of subjects enrolled; changes to regulatory requirements; the need to comply with and meet applicable laws and regulations; unexpected adverse events or safety issues; event rates may vary from projections; whether additional clinical trials will be required by regulatory authorities; and the use of cash and having adequate funding, which can vary based on the timing of incurring costs for activities to support our clinical development and any applications for marketing approval, and whether or when the Company begins building any significant commercial infrastructure. There can be no assurance that data from any of our clinical trials will be sufficient to support an application for marketing in any country or that any such application will ever be approved or that the Company will be able to raise additional funding on reasonable terms or at all.
These and other risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Annual Report on Form 10-Q for the quarter ended June 30, 2018. These forward-looking statements speak only as of the date hereof, and Vital Therapies, Inc. disclaims any obligation to update these statements except as may be required by law.
Vital Therapies, Inc.
Vice President, Investor Relations and Business Development
|Vital Therapies, Inc.|
|Condensed Consolidated Balance Sheets|
|(unaudited, in thousands)|
|Cash and cash equivalents||$||31,116||$||56,901|
|Prepaid expenses and other current assets||1,529||1,220|
|Property and equipment, net||2,059||2,155|
|Accounts payable, accrued expenses and other current liabilities||$||8,299||$||10,281|
|Total liabilities and stockholders' equity||$||34,801||$||60,384|
|Vital Therapies, Inc.|
|Condensed Consolidated Statements of Operations|
|(unaudited and in thousands, except share and per share data)|
Ended June 30,
Ended June 30,
|Research and development||$||8,660||$||9,834||$||18,817||$||19,462|
|General and administrative||4,257||2,715||8,592||5,774|
|Total operating expenses||12,917||12,549||27,409||25,236|
|Loss from operations||(12,917||)||(12,549||)||(27,409||)||(25,236||)|
|Net loss per share, basic and diluted||$||(0.30||)||$||(0.29||)||$||(0.64||)||$||(0.67||)|
|Weighted-average common shares|
|outstanding, basic and diluted||42,368,973||42,207,376||42,368,919||37,452,655|